$2.80
1.82%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US09203E1055
Symbol
BDTX

Black Diamond Therapeutics Inc Stock price

$2.80
-0.03 1.06% 1M
+0.89 46.60% 6M
+0.66 30.84% YTD
-3.30 54.10% 1Y
-0.27 8.79% 3Y
-27.22 90.67% 5Y
-36.68 92.91% 10Y
-36.68 92.91% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.05 1.82%
ISIN
US09203E1055
Symbol
BDTX
Industry

Key metrics

Basic
Market capitalization
$159.4m
Enterprise Value
$16.6m
Net debt
positive
Cash
$142.8m
Shares outstanding
56.9m
Valuation (TTM | estimate)
P/E
11.7 | 8.8
P/S
2.3 | 2.2
EV/Sales
0.2 | 0.2
EV/FCF
0.9
P/B
1.2
Financial Health
Equity Ratio
67.9%
Return on Equity
-83.7%
ROCE
3.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$70.0m | $71.4m
EBITDA
$5.1m | $2.4m
EBIT
$4.7m | $9.7m
Net Income
$14.4m | $18.1m
Free Cash Flow
$17.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
105.8% | 103.0%
EBIT
105.4% | 112.3%
Net Income
117.9% | 126.0%
Free Cash Flow
126.2%
Margin (TTM | estimate)
Gross
-
EBITDA
7.2% | 3.3%
EBIT
6.7%
Net
20.6% | 25.3%
Free Cash Flow
25.5%
More
EPS
$0.2
FCF per Share
$0.3
Short interest
17.4%
Employees
24
Rev per Employee
$0.0
Show more

Is Black Diamond Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Black Diamond Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Black Diamond Therapeutics Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Black Diamond Therapeutics Inc forecast:

Buy
91%
Hold
9%

Financial data from Black Diamond Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
70 70
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
32% 32%
29%
- Research and Development Expense 45 45
22% 22%
64%
5.05 5.05
106% 106%
7%
- Depreciation and Amortization 0.34 0.34
8% 8%
0%
EBIT (Operating Income) EBIT 4.71 4.71
105% 105%
7%
Net Profit 14 14
118% 118%
21%

In millions USD.

Don't miss a Thing! We will send you all news about Black Diamond Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Black Diamond Therapeutics Inc Stock News

Positive
Seeking Alpha
9 days ago
Black Diamond Therapeutics' Silvertinib (BDTX-1535) targets non-classical EGFR mutations in NSCLC, addressing an unmet need left by current standard Osimertinib. Preliminary Phase 2 results for Silvertinib are promising, with full enrollment completed and further data expected in Q4 2025. Early data of Silvertinib in the first line setting will be a major catalyst.
Neutral
The Motley Fool
27 days ago
Black Diamond (BDTX) Q2 Loss Narrows 47%
Neutral
GlobeNewsWire
27 days ago
CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.
More Black Diamond Therapeutics Inc News

Company Profile

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Head office United States
CEO Mark Velleca
Employees 24
Founded 2014
Website www.blackdiamondtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today